An excerpt of clinical practice guideline of prevention and treatment of metabolic dysfunction-associated （non-alcoholic） fatty liver disease （2024 edition）
- VernacularTitle:《代谢相关（非酒精性）脂肪性肝病防治指南（2024年版）》解读
- Author:
Jianing KONG
1
;
Binbin ZHANG
2
;
Junping SHI
2
Author Information
- Publication Type:Journal Article
- Keywords: Non-alcoholic Fatty Liver Disease; Prevention; Treatment; Guideline
- From: Journal of Clinical Hepatology 2024;40(9):1767-1770
- CountryChina
- Language:Chinese
- Abstract: With further in-depth studies on non-alcoholic fatty liver disease （NAFLD）， new evidence， concepts， and methods continue to emerge. Chinese Society of Hepatology， Chinese Medical Association， comprehensively updated and revised the previous guidelines based on the latest research advances in fatty liver disease in China and globally and released Clinical practice guideline of prevention and treatment of metabolic dysfunction-associated （non-alcoholic） fatty liver disease （2024 edition）. This article introduces the updates in the new edition of the guideline from the aspects of related terms （metabolic associated fatty liver disease ［MAFLD］）， clinical typing and staging， diagnostic criteria， and natural history. The guideline particularly emphasizes the importance of screening， assessment， and noninvasive diagnosis of progressive liver fibrosis in disease management and proposes active multidisciplinary collaboration in the management of MAFLD. With the implementation and application of the new edition of the guideline， the standardization of screening， diagnosis， treatment and follow-up of MAFLD patients in China will be further improved to improve the prognosis of the majority of patients.
